Table 5.
Baseline clinical characteristics and outcomes in patients infected with RSVa
| Characteristic | Oral ribavirin therapy (n = 48) | Nonribavirin therapy (n = 12) | P value |
|---|---|---|---|
| Age, median years (IQR) | 50 (32–59) | 48 (41–60) | 0.50 |
| Male gender | 27 (56) | 6 (50) | 0.70 |
| Site of infection | 0.17 | ||
| Upper respiratory infection | 13 (27) | 6 (50) | |
| Lower respiratory infection | 35 (73) | 6 (50) | |
| Diagnosis | 0.36 | ||
| Acute myeloid leukemia | 25 (52) | 3 (25) | |
| Acute lymphoblastic leukemia | 10 (21) | 3 (25) | |
| Chronic myeloid leukemia | 1 (2) | 0 | |
| Non-Hodgkin lymphoma | 4 (8) | 2 (17) | |
| Other | 8 (17) | 4 (33) | |
| HSCT | 26 (54) | 8 (67) | 0.43 |
| Type of transplant | >0.99 | ||
| Allogeneic, sibling | 14/48 (54) | 4/12 (50) | |
| Allogeneic, family donor other than sibling | 2/48 (8) | 1/12 (12) | |
| Allogeneic, unrelated | 10/48 (38) | 3/12 (38) | |
| Stem cell source | 0.23 | ||
| Bone marrow | 11/48 (42) | 5/12 (63) | |
| Peripheral blood | 15/48 (58) | 3/12 (37) | |
| Underlying disease state | 0.13 | ||
| Remission | 5 (10) | 4 (33) | |
| Minimal residual | 8 (17) | 3 (25) | |
| Persistent/relapse | 33 (69) | 5 (42) | |
| Unclear | 2 (4) | 0 | |
| McCabe score | 0.16 | ||
| Nonfatal | 0 | 0 | |
| Ultimately fatal | 36 (75) | 6 (50) | |
| Rapidly fatal | 12 (25) | 6 (50) | |
| Charlson comorbidity score, median (IQR) | 2 (2–2) | 2 (2–2) | 0.48 |
| Curb-65 | 0.91 | ||
| Score 0–1 | 39 (81) | 10 (83) | |
| Score 2–5 | 9 (19) | 2 (17) | |
| Pneumonia severity index | 0.62 | ||
| I | 2 (4) | 2 (17) | |
| II | 8 (17) | 0 | |
| III | 16 (33) | 4 (33) | |
| IV | 17 (36) | 3 (25) | |
| V | 5 (10) | 3 (25) | |
| Immunosuppressive agent use | 15 (31) | 2 (17) | 0.48 |
| Methylprednisolone use | 32 (67) | 8 (67) | >0.99 |
| Initial ANC (/mm3), median (IQR) | 1,262 (57–4,445) | 1,367 (681–4,125) | 0.62 |
| Initial creatinine, median (IQR) | 0.7 (0.5–0.9) | 1.1 (0.6–2.1) | 0.05 |
| Initial bilirubin | 0.7 (0.6–1.3) | 0.8 (0.6–1.6) | 0.39 |
| Use of intravenous immunoglobulin | 15 (31) | 1 (8) | 0.15 |
| Follow-up viral test | 38 (79) | 2 (17) | <0.001 |
| Negative result for viral RNA detection | 24/38 (63) | 0 | 0.15 |
| Length of hospital stay after viral infection, median days (IQR) | 24.0 (13.5–47.5) | 5.0 (2.5–10.0) | 0.002 |
| Coinfection | 16 (33) | 4 (33) | >0.99 |
| Bacterial | 9/16 (56) | 3/4 (75) | |
| Viral | 5/16 (31) | 1/4 (25) | |
| Fungal | 2/16 (13) | 0 | |
| Overall mortality | 13 (27) | 4 (33) | 0.73 |
| Underlying respiratory death | 5 (10) | 3 (25) | 0.19 |
a
Data are presented as numbers (%) of patients unless otherwise specified.